Recent developments include capital raises, clinical trial partnerships, new data releases, and leadership appointments that reflect active pipeline advancement and operational execution.

• Calidi partnered with TransferAI to streamline IND submission for tumor virotherapy CLD-401, enhancing regulatory process efficiency [N1].
• The company released new data on its RedTail mechanism for cancer treatment, contributing to scientific validation of its platform [N2].
• Calidi closed a $6 million offering to advance its cancer immunotherapy pipeline, strengthening its financial resources [N3].
• The company reported a 23% reduction in net loss in fiscal Q2, indicating progress in managing expenses [N4].
• Calidi invited investors to a webinar on precision genetic medicine advances, highlighting its focus on innovative therapeutic approaches [N5].
• An agreement was announced for immediate exercise of warrants, anticipating $4.6 million in proceeds to support operations [N6].
• Leadership was strengthened with new CEO and Chief Medical Officer appointments, supporting strategic and clinical development [N7].
• Calidi received FDA IND clearance for CLD-201 in solid tumor treatment, enabling clinical trial initiation [N8].

Calidi’s advancement of its cancer immunotherapy pipeline through clinical trials and regulatory clearances, such as the FDA IND clearance for CLD-201, supports its development progress. The company’s recent capital raises provide funding to support ongoing research and clinical activities. Strategic partnerships, including those with TransferAI and Avance Clinical, facilitate clinical trial execution and regulatory submissions. Leadership strengthening with experienced executives may enhance operational execution. The company’s focus on innovative oncolytic virus therapies and novel mechanisms like RedTail may offer potential therapeutic benefits in oncology.

Calidi faces risks typical of early-stage biotechnology companies, including the possibility of clinical trial failures, regulatory hurdles, and delays in product development. The company has a history of net losses and negative cash flows, with substantial accumulated deficits, indicating ongoing capital needs. Dependence on key personnel and the ability to secure additional funding are critical risks. Market competition and technological innovation by competitors may impact Calidi’s development and commercialization prospects. The company’s status as an emerging growth and smaller reporting company may limit certain disclosures and investor protections.

Calidi Biotherapeutics’ moat is primarily based on its proprietary oncolytic virus therapy platforms and its development pipeline targeting cancer immunotherapy. The company’s focus on novel mechanisms such as the RedTail mechanism and its clinical-stage product candidates, including CLD-101 and CLD-201, provide potential differentiation. However, as an early-stage biotechnology company without commercial products, its competitive position depends on successful clinical development, regulatory approvals, and eventual market acceptance. The company’s partnerships and intellectual property portfolio contribute to its strategic positioning, but the biotechnology sector’s inherent risks and competition remain significant.

• Clinical and Regulatory Risk: Calidi’s product candidates require extensive clinical testing and regulatory approval, with inherent risks of failure or delays that could impact development timelines and commercialization potential.
• Financial Risk: The company has recurring net losses and negative cash flows, with a significant accumulated deficit. Continued operations depend on raising additional capital, which may not be available on favorable terms.
• Operational Risk: Dependence on key personnel and the ability to execute clinical trials and partnerships effectively are critical to advancing the pipeline.
• Market and Competitive Risk: Competition from other biotechnology companies developing cancer immunotherapies and oncolytic virus therapies may affect Calidi’s market position and product acceptance.

• Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing oncolytic virus therapies and cancer immunotherapy platforms [S1].
• The company operates as a single reportable segment managing research, development, and commercialization efforts on a consolidated basis [S1].
• Calidi's product candidates are subject to long development cycles and require extensive preclinical and clinical testing and regulatory approval before commercialization [S1].
• The company has not generated any revenues from commercial products to date [S1].
• Calidi expects to generate future income from license fees, funded R&D agreements, milestone payments, product sales, government and third-party funding, and royalties, dependent on regulatory approval and commercialization success [S1].
• The company has experienced recurring losses and negative cash flows, with a significant accumulated deficit of $141.6 million as of December 31, 2025 [S1].
• For the quarter ended March 31, 2026, Calidi reported a net loss of $4.1 million and basic and diluted EPS of -$0.43 per share [S2].
• As of March 31, 2026, Calidi had cash and equivalents of $9.6 million, current assets of $7.35 million, current liabilities of $3.84 million, a current ratio of 1.92, and a cash ratio of 2.5, indicating liquidity to support near-term operations [S2].
• The company completed a $6 million offering in March 2026 to advance its cancer immunotherapy pipeline [N3].
• Calidi has partnerships to support clinical trial activities, including with TransferAI to streamline IND submission for tumor virotherapy CLD-401 and with Avance Clinical for trial initiation in Australia [N1][N3].
• Calidi released new data on its RedTail mechanism for cancer treatment in April 2026 [N2].
• The company has received FDA IND clearance for CLD-201 in solid tumor treatment [N8].
• Calidi has strengthened its leadership team with appointments of a new CEO, Eric Poma, Ph.D., and Chief Medical Officer, Guy Travis Clifton, in 2025 [N7].
• The company initiated recruitment for a Phase 1 clinical trial of CLD-101 targeting recurrent glioma [N7].
• Calidi is an emerging growth company and a smaller reporting company, which provides certain exemptions and reduced reporting requirements under the JOBS Act [S1].
• The company’s internal controls and disclosure controls were evaluated as effective as of December 31, 2025 [S1].
• Calidi’s business is subject to risks common to early-stage biotech companies, including clinical trial failure, regulatory approval challenges, competition, dependence on key personnel, and the need for additional capital [S1].